- Home
- TACH vs XFOR Comparison
TACH vs XFOR Comparison
Compare TACH & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$4.03
Company Overview
Basic Information| Metric | TACH | XFOR |
|---|---|---|
| Founded | 2024 | 2014 |
| Country | United States | United States |
| Employees | N/A | 143 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 356.0M | 407.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TACH | XFOR |
|---|---|---|
| Price | $10.29 | $4.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $25.20 |
| AVG Volume (30 Days) | 58.6K | ★ 580.2K |
| Earning Date | 01-01-0001 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,263.94 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $39.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.03 | $0.17 |
| 52 Week High | $10.38 | $6.63 |
Technical Indicators
Market Signals| Indicator | TACH | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 47.94 | 54.96 |
| Support Level | $10.26 | $3.38 |
| Resistance Level | $10.30 | $4.34 |
| Average True Range (ATR) | 0.02 | 0.30 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 14.29 | 50.31 |
Price Performance
Historical Comparison TACH
XFOR
About TACH Titan Acquisition Corp. Class A Ordinary Shares
Titan Acquisition Corp is a blank check company.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.